Lexeo Therapeutics LXEO 深 滬
等待開盤 10-29 09:30:00 美东时间
10.08
+0.240
+2.44%
華盛通- 最 高10.315
- 今 開9.84
- 成交量 107.04万股
- 最 低 9.50
- 昨 收 9.84
- 總市值 3.35亿
- 52周最高 11.72
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.45
- 委 比 64.71%
- 總股本 3319.70万
- 歷史最高 22.33
- 量 比 0.98
- 振 幅 8.28%
- 歷史最低 1.45
- 每 手 1
- 風險率 1.92%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, Oct. 21, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Conventional small molecule approaches hav...
10-21 21:20
Lexeo Therapeutics Announces $135M Public Offering
Lexeo Therapeutics, Inc. ( ($LXEO) ) has shared an update. On October 16, 2025,...
10-18 05:48
Lexeo Therapeutics launches stock and warrant offering
Lexeo Therapeutics (NASDAQ:LXEO) on Thursday said it has started an underwritten public offering and concurrent private placement of its common stock and pre-funded warrants. The biotech company plans...
10-17 04:37
Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement
Lexeo Therapeutics announced an underwritten public offering and concurrent private placement, raising approximately $135 million in gross proceeds. The company offered 15,625,000 shares of common stock at $8.00 per share, with an option for underwriters to purchase an additional 2,343,750 shares. Additionally, Lexeo sold pre-funded warrants for 1,250,015 shares of common stock to Balyasny Asset Management at $7.9999 per warrant in a private plac...
10-17 03:29
Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
<p>Lexeo Therapeutics has initiated an underwritten public offering and concurrent private placement of its common stock and pre-funded warrants. The company also granted underwriters a 30-day option to purchase additional shares. The private placement involves Balyasny Asset Management, exempt from SEC registration. The offering and private placement are subject to market conditions, and no assurances are given regarding completion. Leerink Part...
10-16 20:32
美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
Guggenheim Initiates Coverage On Lexeo Therapeutics with Buy Rating, Announces Price Target of $30
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Buy rating and announces Price Target of $30.
10-15 22:26
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -- Ohio State researchers recently solved a critical mystery explaining why som...
10-08 22:58
